$NGSX Completes Phase 2 Enrollment Of NGX-1998 Topical Liquid Capsaicin Formulation Trial

NeurogesX Completes Phase 2 Enrollment Of NGX-1998 Topical Liquid Capsaicin Formulation Trial: "SAN MATEO, Calif., June 16, 2011 /PRNewswire/ — NeurogesX, Inc. (NASDAQ:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN). NGX-1998 is being developed to provide safety, efficacy and tolerability that is at least comparable to Qutenza® (capsaicin) 8% patch with a shorter treatment time. A total of 183 patients were enrolled in the Phase 2 study."